Influence of simvastatin on apoB-100 Secretion in non-obese subjects with mild hypercholesterolemia

Lipids

Volumn 45, Issue 6, 2010, Pages 491-500

  Berthold, Heiner K ^b   Mertens, Jessica ^a   Birnbaum, Julia ^a   Brämswig, Susanne ^a   Sudhop, Thomas ^a   Barrett, P Hugh R ^c   Von Bergmann, Klaus ^a   Gouni Berthold, Ioanna ^d  

^a UNIVERSITY OF BONN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Apolipoprotein B 100; Cholesterol; Gas chromatography mass spectrometry; Kinetics; Lipoprotein; Multicompartmental modeling; Simvastatin; Stable isotopes; Statin; Turnover

Indexed keywords

APOLIPOPROTEIN B100; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; HYPOCHOLESTEROLEMIC AGENT;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CROSSOVER PROCEDURE; DIET RESTRICTION; DISEASE SEVERITY; EVENING DOSAGE; HUMAN; HYPERCHOLESTEROLEMIA; ISOTOPE LABELING; KINETICS; LIPOPROTEIN SECRETION; LONG TERM CARE; MALE; MORNING DOSAGE; OBESITY; PROTEIN DEGRADATION; PROTEIN METABOLISM; AGED; METABOLISM; MIDDLE AGED;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN B-100; CHOLESTEROL, LDL; CROSS-OVER STUDIES; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; OBESITY; SIMVASTATIN;

EID: 77955662666     PISSN: 00244201     EISSN: 15589307     Source Type: Journal    
DOI: 10.1007/s11745-010-3420-5     Document Type: Article

References (37)

1. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med 335:1001-1009
2. Scandinavian Simvastatin Survival Study Group (1994) Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 334:1383-1389
3. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland coronary prevention study group. N Engl J Med 333:1301-1307
4. Bilheimer DW, Grundy SM, Brwon MS, Goldstein JL (1983) Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoproteins from plasma in familial hypercholesterolemia heterozygotes. Proc Natl Acad Sci USA 80:4124-4128
5. Marais AD, Naoumova RP, Firth JC, Penny C, Neuwirth CK, Thompson GR (1997) Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia. J Lipid Res 38:2071-2078
6. Schaefer EJ, McNamara JR, Tayler T, Daly JA, Gleason JL, Seman LJ, Ferrari A, Rubenstein JJ (2004) Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects. Am J Cardiol 93:31-39
7. Dixon JL, Ginsberg HN (1993) Regulation of hepatic secretion of apolipoprotein B-containing lipoproteins: Information obtained from cultured liver cells. J Lipid Res 34:167-179
8. Sniderman AD, Cianflone K (1993) Substrate delivery as a determinant of hepatic apoB secretion. Arterioscler Thromb 13:629-636
9. Cummings MH, Watts GF, Pal C, Umpleby M, Hennessy TR, Naoumova R, Sonksen PH (1995) Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in obesity: A stable isotope study. Clin Sci (Lond) 88:225-233
10. Cummings MH, Watts GF, Umpleby AM, Hennessy TR, Naoumova R, Slavin BM, Thompson GR, Sonksen PH (1995) Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM. Diabetologia 38:959-967
11. Duvillard L, Pont F, Florentin E, Galland-Jos C, Gambert P, Verges B (2000) Metabolic abnormalities of apolipoprotein B-containing lipoproteins in non-insulin-dependent diabetes: A stable isotope kinetic study. Eur J Clin Invest 30:685-694
12. Myerson M, Ngai C, Jones J, Holleran S, Ramakrishnan R, Berglund L, Ginsberg HN (2005) Treatment with high-dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia. J Lipid Res 46:2735-2744
13. Ouguerram K, Magot T, Zair Y, Marchini JS, Charbonnel B, Laouenan H, Krempf M (2003) Effect of atorvastatin on apolipoprotein B-100 containing lipoprotein metabolism in type-2 diabetes. J Pharmacol Exp Ther 306:332-337
14. Chan DC, Watts GF, Barrett PH, Mori TA, Beilin LJ, Redgrave TG (2002) Mechanism of action of a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor on apolipoprotein B-100 kinetics in visceral obesity. J Clin Endocrinol Metab 87:2283-2289
15. Thompson GR, Naoumova RP, Watts GF (1996) Role of cholesterol in regulating apolipoprotein B secretion by the liver. J Lipid Res 37:439-447
16. Pease RJ, Leiper JM (1996) Regulation of hepatic apolipoprotein- B-containing lipoprotein secretion. Curr Opin Lipidol 7:132-138
17. Burstein M, Scholnick HR, Morfin R (1970) Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res 11:583-595
18. Egusa G, Brady DW, Grundy SM, Howard BV (1983) Isopropanol precipitation method for the determination of apolipoprotein B specific activity and plasma concentrations during metabolic studies of very low density lipoprotein and low density lipoprotein apolipoprotein B. J Lipid Res 24:1261-1267
19. Berthold HK, Reeds PJ, Klein PD (1995) Isotopic evidence for the differential regulation of arginine and proline synthesis in man. Metabolism 44:466-473
20. Berthold HK, Hachey DL, Reeds PJ, Thomas OP, Hoeksema S, Klein PD (1991) Uniformly 13C-labeled algal protein used to determine amino acid essentiality in vivo. Proc Natl Acad Sci USA 88:8091-8095
21. Khan B, Fungwe TV, Wilcox HG, Heimberg M (1990) Cholesterol is required for secretion of very-low-density lipoprotein: In vivo studies. Biochim Biophys Acta 1044:287-304
22. Khan BK, Wilcox HG, Heimberg M (1989) Cholesterol is required for secretion of very-low-density lipoprotein by rat liver. Biochem J 254:807-816
23. Ginsberg HN, Le NA, Short MP, Ramakrishnan R, Desnick RJ (1987) Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. J Clin Invest 80:1692-1697
24. Vega GL, East C, Grundy SM (1988) Lovastatin therapy in familial dysbetalipoproteinemia: Effects on kinetics of apolipoprotein B. Atherosclerosis 70:131-143
25. Vega GL, Krauss RM, Grundy SM (1990) Pravastatin therapy in primary moderate hypercholesterolemia: Changes in metabolism of apolipoprotein B-containing lipoproteins. J Intern Med 227:81-94
26. Watts GF, Cummings MH, Umpleby M, Quiney JR, Naoumova R, Thompson GR, Sönkesen PH (1995) Simvastatin decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolemia: Pathophysiological and therapeutic implications. Eur J Clin Invest 25:559-567
27. Arad Y, Ramakrishnan R, Ginsberg HN (1990) Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoBcontaining lipoproteins: Implications for the pathophysiology of apoB production. J Lipid Res 31:567-582
28. Grundy SM, Vega GL (1985) Influence of mevinolin on metabolism of low density lipoproteins in primary moderate hypercholesterolemia. J Lipid Res 26:1464-1475
29. Watts GF, Moroz P, Barrett PH (2000) Kinetics of very-lowdensity lipoprotein apolipoprotein B-100 in normolipidemic subjects: Pooled analysis of stable-isotope studies. Metabolism 49:1204-1210
30. Benitez S, Ordonez-Llanos J, Franco M, Marin C, Paz E, Lopez- Miranda J, Otal C, Perez-Jimenez F, Sanchez-Quesada JL (2004) Effect of simvastatin in familial hypercholesterolemia on the affinity of electronegative low-density lipoprotein subfractions to the low-density lipoprotein receptor. Am J Cardiol 93:414-420
31. Welty FK, Lichtenstein AH, Barrett PH, Dolnikowski GG, Schaefer EJ (1999) Human apolipoprotein (Apo) B-48 and ApoB-100 kinetics with stable isotopes. Arterioscler Thromb Vasc Biol 19:2966-2974
32. Lamon-Fava S, Diffenderfer MR, Barrett PH, Buchsbaum A, Matthan NR, Lichtenstein AH, Dolnikowski GG, Horvath K, Asztalos BF, Zago V, Schaefer EJ (2007) Effects of different doses of atorvastatin on human apolipoprotein B-100, B-48, and A-I metabolism. J Lipid Res 48:1746-1753
33. Malmendier CL, Lontie JF, Delcroix C, Magot T (1989) Effect of simvastatin on receptor-dependent low density lipoprotein catabolism in normocholesterolemic human volunteers. Atherosclerosis 80:101-109
34. Parhofer KG, Barrett PH, Dunn J, Schonfeld G (1993) Effect of pravastatin on metabolic parameters of apolipoprotein B in patients with mixed hyperlipoproteinemia. Clin Investig 71:939-946
35. Cuchel M, Schaefer EJ, Millar JS, Jones PJ, Dolnikowski GG, Vergani C, Lichtenstein AH (1997) Lovastatin decreases de novo cholesterol synthesis and LDL Apo B-100 production rates in combined-hyperlipidemic males. Arterioscler Thromb Vasc Biol 17:1910-1917
36. Gaw A, Packard CJ, Murray EF, Lindsay GM, Griffin BA, Caslake MJ, Vallance BD, Lorimer AR, Shepherd J (1993) Effects of simvastatin on apoB metabolism and LDL subfraction distribution. Arterioscler Thromb 13:170-189
37. Magkos F, Patterson BW, Mittendorfer B (2007) Reproducibility of stable isotope-labeled tracer measures of VLDL-triglyceride and VLDL-apolipoprotein B-100 kinetics. J Lipid Res 48:1204-1211